|Day Low/High||0.01 / 0.01|
|52 Wk Low/High||0.00 / 0.95|
Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.
A look at how lawsuits and FDA changes could impact the industry.
Why the name is sagging, and what it will take to spur the sector higher.
Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.
Markets continue to meander slightly lower as we are near to closing out another trading week as the holidays approach. Egalet is up 15% on a bounce from over-sold conditions and solid trial results from Egalet-002, a drug abuse-deterrent, extended...
The market is extremely flat today as we hit midday. Equities are about as exciting right now as the Rams offense was just hours ago on Thursday Night Football. Two of my favorite small biopharma names, Egalet and Cara Therapeutics , are on the way...
The worst appears to be over for this sector; we could see big growth ahead.